Between 2024 and 2026, Slovenia went through one of the most important cannabis policy debates in its recent history. What initially appeared to be a relatively straightforward attempt to legalise cannabis for limited personal use developed into a much more complex process involving public health, youth protection, EU law, regulatory coherence, political timing and coordinated civil society advocacy.
The Slovenian case is particularly interesting because two very different legislative paths developed in parallel. One concerned cannabis for medical and scientific purposes and was ultimately adopted within an established regulatory and healthcare framework. The second sought to legalise cannabis for limited personal use, including home cultivation, possession and free transfer between adults. It was this second proposal that generated substantial public health and legal concerns and ultimately failed to become law.
From a public health perspective, the debate went far beyond the question of whether adults should be allowed to use cannabis. Experts and civil society organisations raised concerns about the broader consequences of increased availability and normalisation, particularly for children, adolescents and young adults. The discussion included mental health risks, dependence, increasing THC potency, impaired driving, family-related harms, public safety, pressure on treatment and mental health services, and the possible effects of changing social norms around cannabis use.
An equally important part of the story concerned the legal architecture of the European Union. Once the proposed legislation entered the EU Technical Regulation Information System, or TRIS, the debate was no longer purely domestic. In October 2025, the European Commission issued a Detailed Opinion that raised concerns about the proposal’s compatibility with EU obligations, including questions related to unauthorised distribution, legal certainty and cross-border effects. The resulting standstill period was extended until February 2026, significantly changing the political and legislative timetable.
Because the standstill coincided with the period leading into Slovenia’s 2026 parliamentary elections, the proposal lost its legislative window. Importantly, the draft was not substantially revised during the standstill period to address the concerns raised at EU level. The process therefore ended without adoption.
The case also demonstrates the potential role of coordinated public health advocacy. Institute for Research and Development “Utrip”, working in close cooperation with the Slovenian NCD Alliance and other partners, helped coordinate a broader civil society response. Advocacy combined scientific evidence, legal analysis, public communication, participation in parliamentary debates and engagement with European and international partners. Rather than framing the issue only as a debate between prohibition and individual freedom, the coalition consistently brought attention back to population health, youth protection, regulatory responsibility and the possible unintended consequences of policy change.
One of the most important lessons from Slovenia is therefore that cannabis policy reform is not linear and not inevitable. Political support alone does not determine the outcome. Legal feasibility, institutional readiness, quality of policy design, scientific evidence, implementation capacity and timing all matter.
The Slovenian experience also illustrates an important distinction that is often lost in public debate: medical cannabis policy and the legalisation of cannabis for non-medical personal use are fundamentally different policy areas. In Slovenia, the medical and scientific framework succeeded precisely because it was embedded within existing regulatory systems, while the personal-use proposal encountered unresolved legal, public health and implementation challenges.
For policymakers, public health professionals and civil society organisations elsewhere in Europe, the Slovenian experience offers a practical case study of how cannabis policy can evolve when national politics, public health evidence, EU law and advocacy intersect. It also provides an example of how civil society can move beyond reactive opposition and instead participate strategically in legislative and regulatory processes at both national and European levels.
The publication below presents the Slovenian experience in a concise and visual format, including the main stages of the legislative process, the role of the TRIS procedure, the key public health arguments, international evidence and the advocacy approach used during the process.
We hope the publication will be useful to policymakers, prevention professionals, public health advocates and civil society organisations facing similar cannabis policy debates in their own countries.
You can find more information in the attached publication: